Business Context and Reporting Period
CareCloud, Inc. (MTBC) filed a Current Report on Form 8-K dated January 27, 2022, reporting material definitive agreements and amendments to its capital structure. The company, incorporated in Delaware, operates in the healthcare technology sector. The filing details a new preferred stock offering and a loan modification with Silicon Valley Bank (SVB).
Key Financial Metrics and Capital Structure
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The financial data provided relates exclusively to a capital raise and debt restructuring:
- Series B Preferred Stock Offering: The company agreed to sell 1,000,000 shares of 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock at $25.00 per share.
- Net Proceeds: Anticipated net proceeds are approximately $23.1 million (prior to the exercise of an underwriters' option for an additional 150,000 shares).
- Dividend Rate: 8.75% annually on the $25.00 liquidation preference ($2.1875 per share per year), payable monthly.
- Debt Modification: SVB consented to the payment of dividends on the Series B stock and the use of proceeds to redeem a portion of the 11% Series A Preferred Stock.
Material Changes Versus Prior Period
The filing outlines significant changes to the company's equity and debt instruments compared to the prior period:
- Series A Reduction: The authorized shares of 11% Series A Preferred Stock were decreased from 6,750,000 to 5,350,000 shares via a Seventh Amendment to the Certificate of Designations.
- Series B Creation: A new class of equity, the 8.75% Series B Preferred Stock, was authorized with up to 1,640,000 shares available for issuance.
- Capital Allocation: Proceeds from the Series B offering are designated to partially redeem the higher-cost Series A Preferred Stock (11% dividend rate) and fund future Series B dividend payments.
Guidance, Outlook, and Risks
The filing does not contain forward-looking operational guidance, revenue forecasts, or management commentary on business outlook. Key terms and contingencies regarding the new securities include:
- Closing Date: The Series B offering is expected to close on or about February 2, 2022.
- Redemption Terms: The Series B stock is redeemable at the company's option starting February 15, 2024, at a price of $25.75 per share, decreasing annually to $25.00 per share after February 15, 2027.
- Voting Rights: Holders generally have no voting rights but may elect two additional directors if dividends are unpaid for 18 or more monthly periods.
- Liquidation Preference: Series B ranks senior to common stock and on parity with Series A, but junior to all existing and future indebtedness.
Investor Verification Checklist
- Verify the final closing date of the Series B offering and the actual net proceeds received after underwriting fees.
- Confirm the specific amount of Series A Preferred Stock redeemed using the proceeds from the Series B offering.
- Review the full text of the Sixth Loan Modification Agreement with SVB for any covenants restricting future operations or dividends.
- Monitor the company's ability to meet the monthly dividend obligations on the new Series B stock to avoid triggering additional director voting rights.